CatchMe Theraputics

Company Overview

Snapshot

Founded in August 2021 by Yael Tsalenchuck, CatchMe Theraputics operated with 1–10 employees. The company secured funding in one round from one investor, FutuRx, before ceasing operations in August 2026.

Business overview

CatchMe Theraputics is a Health Tech & Life Sciences company focused on developing precision medicine solutions for epitranscriptome machinery. The company's core technology involves specific inhibition based on the in vivo biological binding preference of targeted proteins, with a versatile platform designed to target various methyl binding proteins and indications. Operating in the Pharma & Medical Biotechnology sector, CatchMe Theraputics serves global and Israeli markets, focusing on drug discovery and development for healthcare and life sciences, including laboratories, patients, biotechnology, and pharmaceuticals.

Company Intelligence Q&A

What is CatchMe Theraputics' primary focus?

CatchMe Theraputics focuses on precision medicine for epitranscriptome machinery, developing solutions for specific inhibition based on the in vivo biological binding preference of targeted proteins.

When was CatchMe Theraputics founded?

CatchMe Theraputics was founded in August 2021.

Who is a founder of CatchMe Theraputics?

Yael Tsalenchuck is a founder of CatchMe Theraputics, serving as CSO.

What is the current status of CatchMe Theraputics?

CatchMe Theraputics ceased to operate in August 2026.

Which investor participated in CatchMe Theraputics' funding round?

In December 2021, FutuRx participated in a Pre-Seed funding round for CatchMe Theraputics.